BCD 101
Alternative Names: BCD-101Latest Information Update: 01 Jan 2026
At a glance
- Originator Bichedam
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Essential hypertension
Most Recent Events
- 11 Sep 2025 Phase-I clinical trials in Essential hypertension (In volunteers) in South Korea (PO) (NCT07282145)